Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | GMNN | O75496 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | THPO | P40225 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3069757 | 0.72 | — | — | |
| SCHEMBL341630 | 0.69 | CYP2C19 (0.47) | HSD17B10CYP2C19ALDH1A1LMNAKDM4E | |
| SCHEMBL16924674 | 0.67 | — | — | |
| SCHEMBL11127551 | 0.67 | — | — | |
| SCHEMBL1760612 | 0.67 | KMT2A (0.39) | HSD17B10CYP2C19ALDH1A1LMNAKDM4E | |
| SCHEMBL5841715 | 0.67 | — | — | |
| SCHEMBL9669228 | 0.65 | — | — | |
| SCHEMBL9838493 | 0.65 | CYP2C19 (0.38) | HSD17B10CYP2C19ALDH1A1LMNAKDM4E | |
| SCHEMBL16274501 | 0.65 | — | — | |
| SCHEMBL11184089 | 0.65 | CYP2C19 (0.37) | HSD17B10CYP2C19ALDH1A1LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| US-20240074995-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2024-03-07 | — | — | US | disclosed |
| US-11793777-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FIRST WAVE BIO, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11744812-B2 | Methods of treatment | FIRST WAVE BIO, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20230201143-A1 | METHODS OF TREATMENT | FIRST WAVE BIO, INC. | 2023-06-29 | — | — | US | disclosed |
| WO-2023118074-A1 | COMPRESSIBLE AND FREE FLOWING CO-PROCESSED MESOPOROUS SILICA | UNIVERZA V LJUBLJANI (SI) | 2023-06-29 | — | — | WO | disclosed |
| US-20230190684-A1 | METHODS OF TREATING COVID-19 WITH A NICLOSAMIDE COMPOUND | FIRST WAVE BIO, INC. | 2023-06-22 | — | — | US | disclosed |
| US-20230102999-A1 | DEUTERATED NICLOSAMIDE | FIRST WAVE BIO, INC. | 2023-03-30 | — | — | US | disclosed |
| US-11564896-B2 | Methods of treatment | FIRST WAVE BIO, INC. (US) | 2023-01-31 | — | — | US | disclosed |
| EP-4045480-A1 | PHARMACEUTICAL FORMULATIONS | First Wave Bio, Inc. (US) | 2022-08-24 | — | — | EP | disclosed |
| US-6562363-B1 | Bioadhesive compositions and methods for topical administration of active agents | NOVEN PHARMACEUTICALS, INC. | 2003-05-13 | — | — | US | disclosed |
| US-20020004065-A1 | Compositions and methods to effect the release profile in the transdermal administration of active agents | KANIOS DAVID (US) | 2002-01-10 | — | — | US | disclosed |
| US-6221383-B1 | BLEND OF AT LEAST TWO POLYMERS, OR AT LEAST ONE POLYMER AND A SOLUBLE POLYVINYLPYRROLIDONE, IN COMBINATION WITH A DRUG PROVIDES A PRESSURE-SENSITIVE ADHESIVE COMPOSITION FOR A TRANSDERMAL DRUG DELIVERY SYSTEM | NOVEN PHARMACEUTICALS, INC. | 2001-04-24 | — | — | US | disclosed |
| EP-1021204-A2 | BIOADHESIVE COMPOSITIONS AND METHODS FOR TOPICAL ADMINISTRATION OF ACTIVE AGENTS | NOVEN PHARMACEUTICALS, INC. (US) | 2000-07-26 | — | — | EP | disclosed |
| US-6024976-A | TRANSDERMAL DRUG DELIVERY WITH PRESSURE SENSITIVE ADHESIVE COMPOSITION OF POLYVINYLPYRROLIDONE WITH DRUG IN MULTILAYER PATCH | NOVEN PHARMACEUTICALS, INC. (US) | 2000-02-15 | — | — | US | disclosed |
| WO-1999015210-A2 | BIOADHESIVE COMPOSITIONS AND METHODS FOR TOPICAL ADMINISTRATION OF ACTIVE AGENTS | NOVEN PHARMACEUTICALS, INC. (US) | 1999-04-01 | — | — | WO | disclosed |
| US-5656286-A | BLEND OF TWO POLYMERS; PRESSURE SENSITIVE ADHESIVE | NOVEN PHARMACEUTICALS, INC. (US) | 1997-08-12 | — | — | US | disclosed |
| WO-1996040084-A1 | COMPOSITIONS AND METHODS FOR USE OF PRESSURE SENSITIVE ADHESIVE TRANSDERMAL DEVICES CONTAINING A BIOADHESIVE HUMECTANT | NOVEN PHARMACEUTICALS, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| US-5232441-A | Method of treating schistosomal infestations by iontophoresis | PHYSION S.R.L. (IT) | 1993-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240074995-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | HSD17B10 528/4885CYP2C19 1403/4885ALDH1A1 2174/4885 |
| US-20230190684-A1 | METHODS OF TREATING COVID-19 WITH A NICLOSAMIDE COMPOUND | ACE2, ACE, MME | HSD17B10 2272/4885CYP2C19 12/4885ALDH1A1 3497/4885 |
| US-11744812-B2 | Methods of treatment | ACE2, ACE, SI | HSD17B10 2468/4885CYP2C19 12/4885ALDH1A1 3977/4885 |
| US-20230201143-A1 | METHODS OF TREATMENT | ACE2, ACE, SI | HSD17B10 2422/4885CYP2C19 22/4885ALDH1A1 3889/4885 |
| US-11564896-B2 | Methods of treatment | ACE2, ACE, SI | HSD17B10 2422/4885CYP2C19 22/4885ALDH1A1 3889/4885 |
| US-20230102999-A1 | DEUTERATED NICLOSAMIDE | FH, IDH2, ECHS1 | HSD17B10 470/4885CYP2C19 1410/4885ALDH1A1 2305/4885 |
| US-11793777-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FH, CS, ECHS1 | HSD17B10 502/4885CYP2C19 1305/4885ALDH1A1 2230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.